Orlistat Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia

PHASE4CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

August 26, 2022

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2023

Conditions
Uric Acid
Interventions
DRUG

Orlistat

Orlistat was administered orally on the basis of lifestyle guidance . Orlistat: Take 0.12g (1 capsule) with or within one hour after meals, 3 times a day. Medication time course: continuous administration for a total of 12 weeks.

DRUG

Orlistat placebo

Lifestyle guidance: low-purine diet; orlistat placebo: take 1 capsule with or within one hour after a meal, 3 times a day. Medication time course: continuous administration for a total of 12 weeks.

Trial Locations (1)

200070

Shanghai Tenth People's hospital, Shanghai

All Listed Sponsors
lead

Shanghai 10th People's Hospital

OTHER